AbCellera 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...7891011121314151617...2223»
  • ||||||||||  Journal:  In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron. (Pubmed Central) -  Mar 11, 2022   
    Of all antibodies under EUA, the neutralisation potential of Etesevimab, Bamlanivimab, Casirivimab, Imdevima, Cilgavimab, Tixagevimab, Sotrovimab, and Regdanvimab might be dampened to varying degrees. Our analysis suggests the impact of Omicron on current therapeutic antibodies by the Omicron spike mutations may also apply to current COVID-19 vaccines.
  • ||||||||||  REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche, bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
    Journal:  Antibody escape and global spread of SARS-CoV-2 lineage A.27. (Pubmed Central) -  Mar 11, 2022   
    Moreover, the therapeutic monoclonal antibody Bamlanivimab and partially the REGN-COV2 cocktail fail to block infection by A.27. Our data emphasize the need for continued global monitoring of novel lineages because of the independent evolution of new escape mutations.
  • ||||||||||  Informing a Conceptual Framework for a Patient-Centered Value Assessment of Emerging Therapies for Mild/Moderate COVID-19 (In-person & Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_894;    
    We searched PubMed [December 21, 2021] to identify relevant publications using the string: “(mild OR moderate) AND (COVID OR coronavirus 2019 OR COVID19) AND (bamlanivimab OR estesevimab OR sotrovimab OR casirivimab OR imdevimab OR REGN-COV2) OR (paxlovid) OR (molnupiravir) ” . Potential impacts on productivity and patient costs suggest that therapies for mild/moderate COVID-19 should be assessed with evaluations that include the patient-informed value elements .
  • ||||||||||  bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) / Eli Lilly, etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly
    Trial completion:  BLAZE-1: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (clinicaltrials.gov) -  Mar 7, 2022   
    P2/3,  N=3290, Completed, 
    Potential impacts on productivity and patient costs suggest that therapies for mild/moderate COVID-19 should be assessed with evaluations that include the patient-informed value elements . Active, not recruiting --> Completed
  • ||||||||||  REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche, bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
    Retrospective data, Journal:  The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series. (Pubmed Central) -  Mar 5, 2022   
    The administration of MCA therapy in high-risk pediatric patients in the pediatric ED was well-tolerated with subjective improvement noted in COVID-19 symptoms post-therapy. Further studies are necessary to determine the role MCA therapy may play in reducing morbidity from COVID-19 infection in high-risk pediatric patients.
  • ||||||||||  Journal:  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. (Pubmed Central) -  Mar 3, 2022   
    Together, data suggest Omicron would cause significant humoral immune evasion, while NAbs targeting the sarbecovirus conserved region remain most effective. Our results offer instructions for developing NAb drugs and vaccines against Omicron and future variants.
  • ||||||||||  bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
    Journal:  Impact of New Variants on SARS-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions. (Pubmed Central) -  Feb 24, 2022   
    Our study elucidates the molecular origin of the ability of Beta and Delta variants to evade selected antibodies, such as REGN10933, LY-CoV555, B38, C105 or H11-H4, while being insensitive to others including REGN10987...The substitutions T478K and L452R in Delta variant enhance the associations with ACE2, while P681R promotes recognition by proteases thus facilitating viral entry. The Ab-specific responses of variants highlight how full-atomic structure and dynamics analyses are required for assessing the response to newly emerging variants.
  • ||||||||||  bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
    Journal:  Experience of Rwanda on COVID-19 Case Management: From Uncertainties to the Era of Neutralizing Monoclonal Antibodies. (Pubmed Central) -  Feb 23, 2022   
    Moving forward, as we strive to continue detecting COVID-19 cases as early as possible, and promptly initiate supportive interventions, the use of neutralizing monoclonal antibodies constitutes an attractive and cost-effective therapeutic approach. If this approach is used strategically along with other measures in place (i.e., COVID-19 vaccine roll out, etc.), it will enable us to bring this global battle against the COVID-19 pandemic under full control and with a low case fatality rate.
  • ||||||||||  etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly
    Journal:  COVID-19 updates: NIH outpatient treatment guidelines. (Pubmed Central) -  Feb 23, 2022   
    If this approach is used strategically along with other measures in place (i.e., COVID-19 vaccine roll out, etc.), it will enable us to bring this global battle against the COVID-19 pandemic under full control and with a low case fatality rate. No abstract available
  • ||||||||||  bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
    Review, Journal:  SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. (Pubmed Central) -  Feb 22, 2022   
    In this review, we focus on the impact of RBD mutations in SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI) on ACE2 binding affinity and escape of serum antibody neutralization. We also provide protein structure models to show how the VOC and VOI RBD mutations affect ACE2 binding and allow escape of the virus from the therapeutic antibody, bamlanivimab.
  • ||||||||||  etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly
    Journal:  COVID-19 Updates: Monoclonal Antibodies for COVID-19. (Pubmed Central) -  Feb 19, 2022   
    Availability of open-access codes and application of novel in silico model-based approaches supported the selection of bamlanivimab and identified the lowest dose evaluated in this study that was expected to result in the maximum therapeutic effect before the first-in-human clinical trial. No abstract available
  • ||||||||||  B-Cell Depletion Associated Prolonged COVID-19 and Response to Treatment with Monoclonal Antibodies: A Case Series (Area J, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_868;    
    Those with B-cell depletion due to therapies like Rituximab and Obinutuzumab, often experience more protracted courses, as demonstrated in this cohort. Immunocompetent patients have seroconversion at 7-14 days after symptom onset in most cases, but patients with B-cell depletion may fail to develop neutralizing antibodies weeks to months after.
  • ||||||||||  etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly
    Journal, HEOR:  Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. (Pubmed Central) -  Feb 17, 2022   
    Within 2 months, we closed the gap of the likelihood of receiving mAb, conditional on background positivity rate, between Black and White patients (Black patients 0.238; White patients 0.241). We describe trial infrastructure, lessons learned, and future directions for a culture of learning while doing.